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Objectives: Novel specialty biopharmaceuticals hold great promise for patients 
living with complex and chronic conditions. However, high research and develop-
ment costs, special handling, and other necessary enhancements to patient support 
programs all contribute to frequently higher prices for these products. This study 
sought to assess the value of specialty pharmaceuticals through an examination of 
the clinical, functional, and economic benefits of these treatments for the top three 
disease areas by pharmaceutical spend: rheumatoid arthritis (RA), multiple sclerosis 
(MS), and breast cancer (BC). MethOds: A systematic review of market research and 
cost-effectiveness articles was conducted for each disease area to assess clinical, 
functional, and economic outcomes associated with specialty medicine treatments 
versus the previous standard of care. Results: All RA clinical (ACR) and functional 
(HAQ) outcome articles were classified as positive. The median cost-effectiveness 
ratio was $37,000 per QALY. All MS clinical outcome (relapse rate) articles were posi-
tive. The MS functional outcome (EDSS) findings were less conclusive. The median 
cost-effectiveness ratio was $220,000 per QALY. The majority of BC articles yielded 
statistically inconclusive results for survival. All functional outcome (QLQ-C30) arti-
cles were positive. The median cost-effectiveness ratio was $49,000 per QALY. All 
endpoints reflect a population average treatment response and did not account for 
the presence of patient heterogeneity of treatment effect. cOnclusiOns: Novel 
specialty therapies hold great promise for arresting disease progression and improv-
ing quality of life for the three conditions associated with the highest specialty 
pharmaceutical spending. These findings demonstrate a strong value proposition 
for specialty pharmaceuticals in general, and suggest even greater substantial 
potential individual patient benefit with consideration of patient heterogeneity.
PIH31
RevIsItIng tHe Cost-effeCtIveness of HeRPes ZosteR vaCCInatIon In 
eldeRly PeoPle In tHe UnIted states
Ortega-Sanchez I.
Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA
bAckgROund: Herpes Zoster (HZ) or shingles, common among elderly people, 
increases with age and so does its severe outcomes including post herpetic neuralgia 
(PHN). Although efficacious in immunocompetent adults aged ≥ 50 years, protection 
from a licensed vaccine decreases in time which, faced with increasing disease risks, 
makes age of vaccination crucial. Objectives: To evaluate the cost effectiveness 
of HZ vaccination among adults aged ≥ 50 years and identify the public health and 
economically optimal vaccination age. MethOds: We used a cohort-based decision 
analysis model to compare the age-specific incidence, health care resource utiliza-
tion, costs and quality-adjusted life years (QALYs) related to HZ, PHN and non-pain 
complications among unvaccinated and vaccinated individuals at either age 50, 60 
or 70 years. Health outcomes, resource utilization and costs were projected for the 
US cohorts from 50 to 99 years of age. It incorporates HZ-specific QALY scores for 
duration and intensity of pain and the probabilities for Monte Carlo simulations. 
QALYs gained and cost per QALY gained from vaccination are the primary estimates. 
Sensitivity analyses were conducted on vaccine efficacy duration and other vari-
ables. Results: Vaccinating at age 60 would prevent more shingles cases (26,147 
cases per million persons) followed by vaccinating at age 70 while vaccinating at 
age 50 prevents the less number of shingles cases (21,269 vs. 19,795 respectively). 
However, vaccinating at age 70 would be the strategy with the biggest impact (8,055 
PHN cases prevented), followed by age 60 and then age 50 (4,055 vs. 1,012 PHN cases 
prevented, respectively). Vaccinating at age 70, 60, and 50 would societally cost 
$38,000, $80,000 and $272,000 per QALY saved, respectively. cOnclusiOns: Overall, 
the optimal age for vaccination would be at 70 years. While various uncertainties 
remain, our results were robust based on the sensitivity analyses and the magnitude 
of the differences in outcomes and costs between strategies.
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Objectives: To conduct an economic evaluation comparing a recombinant gonado-
trophin (r-hFSH, follitropin alfa, GONAL-f) with two classes of urinary gonadotro-
phins, hp-HMG (Menopur) and u-FSH (Fostimon) for ovarian stimulation in women 
undergoing in-vitro fertilization (IVF) treatment in The Netherlands MethOds: A 
pharmaco-economic model was developed, simulating each step in IVF protocol 
from start of therapy until either live birth, new IVF treatment cycle, or stopping 
IVF, following a long down-regulation protocol. A decision tree combined with a 
Markov model details progress through each health state, including oocyte retrieval, 
fresh embryo transfer, up to two subsequent cryo-embryo transfers, and (ongoing) 
pregnancy or miscarriage. A health insurer perspective was chosen and the time 
horizon was set to a maximum of three consecutive treatment cycles. Transition 
probabilities and costing data were derived from a real-world observational out-
comes database (Germany), and official tariff lists (The Netherlands). Adverse events 
were considered equal amongst comparators and therefore excluded. The model 
was validated by clinical experts to ensure appropriateness and to local manage-
ment of infertility and applicability. A Monte Carlo simulation with 5,000 iterations 
was undertaken for each strategy to explore uncertainty and to construct uncer-
tainty intervals (UI). Results: Mean total treatment costs were estimated as: € 5,664 
for GONAL-f (95%UI: € 5,167-€ 6,151), € 5,990 for Menopur (95%UI: € 5,498-€ 6,488) and 
€ 5,760 for Fostimon (95%UI: € 5,256-€ 6,246). The probability of a live birth was esti-
mated at 36.1% (95%UI: 27.4%-44.3%), 33.9% (95%UI: 26.2%-41.5%) and 34.1% (95%UI: 
25.9%-41.8%) for GONAL-f, Menopur and Fostimon respectively. Costs per live 
birth estimates are: € 15,674 (GONAL-f), € 16,878 (Fostimon) and € 17,636 (Menopur). 
Probabilistic sensitivity analysis indicates a probability of 72.5% that GONAL-f is 
cost-effective at a willingness-to-pay of € 20,000/live birth. Probabilistic results 
remained constant under several analyses. cOnclusiOns: GONAL-f appears to 
study was set; methods employed; the inclusion of active comparators; and study 
endpoints. Data was extracted from each study using a predefined data extraction 
form. Results: Seventy studies met our inclusion criteria and were included in 
our dataset. Many of these analyses’ have concluded that PET is cost-effective; 38% 
of the cost-effectiveness analyses’ findings indicate ICERs less than $50,000 (2012 
USD). Growth in the cost-effectiveness literature for PET parallels growth of the 
cost-effectiveness literature more broadly with 35% of studies published since 2009. 
Across all years, a smaller proportion of studies examining PET emanated from the 
US than did cost-effectiveness analyses generally (29% vs. 42%). The majority of 
studies examined PET for oncological indications (n= 58; 83%). The most common 
analytical method employed was cost-effectiveness analysis, although two cost-
minimization studies were also identified. Studies typically compared PET to either 
x-ray computed tomographic imaging or usual care. Diagnostic accuracy was the 
most common unit of effectiveness reported. cOnclusiOns: There is substantial 
literature evaluating the cost-effectiveness of PET across a range of indications. Most 
studies have examined diagnostic accuracy and not considered endpoints, such as 
how PET imaging influences clinical decision making or changes patient outcomes.
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Objectives: Centralizing city-wide neonatal total parenteral nutrition (TPN) pro-
duction can reduce medication errors through standardized processes and order 
sets and pediatric pharmacist review. However, it is unclear if the benefits justify 
the cost. The purpose of this study was to determine the costs and benefits of cen-
tralizing city-wide multi-institution neonatal TPN production at a single pediatric 
institution. A second objective was to calculate the error reduction potential by 
centralizing neonatal TPN preparation. MethOds: We performed a cost-benefit 
analysis of neonatal TPN preparation in a large metropolitan area, comparing the 
direct medical costs and benefits of centralized preparation at a large, nonprofit 
tertiary care pediatric hospital by pediatric pharmacists vs. decentralized prepara-
tion at multiple large, nonprofit tertiary care adult hospitals by staff pharmacists. 
Costs of TPN production and courier service were obtained from institution data. 
Medication error rates and costs of errors were obtained from the literature. We 
took the pediatric hospital perspective for a 5-year horizon. A 3% discount rate was 
used. Single-variable sensitivity analyses of medication error costs and error rates 
were performed to test the stability of the outcomes. Results: In 2013 adjusted 
dollars, total costs over 5 years for TPN centralization was $2,028,374 vs. $2,668,398 
for decentralization, a cost savings of $640,024. The primary benefit of TPN centrali-
zation was a decrease in the TPN error rate from 0.075% to 0.050%. Including both 
the costs of TPN production and the costs associated with TPN errors, the net cost 
of TPN centralization was $3,488,374 vs. $4,858,398 for decentralization, a net cost 
savings of $ 1,370,024. TPN centralization remained cost beneficial throughout the 
sensitivity analysis. cOnclusiOns: Centralizing city-wide multi-institutional TPN 
production at a pediatric hospital has the potential to reduce medication errors and 
result in significant cost savings for all participating institutions.
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Objectives: Cost utility analysis (CUA) is the technique of choice for decision 
making, yet the elicitation of utilities in children poses significant challenges. The 
objectives were to examine trends over time and to investigate sources for util-
ity weights used in pediatric CUA. MethOds: The Pediatric Economic Database 
Evaluation (PEDE) Project http://pede.ccb.sickkids.ca/pede maintains a searchable 
database of pediatric economic evaluations published since 1980. Data on study 
characteristics are routinely collected from each citation, and health state descrip-
tions, utility weights, and utility sources are extracted for each CUA. Descriptive 
statistics were used to analyze study characteristics for all studies included in PEDE 
from 1980 to 2012. Results: The PEDE database includes 2,485 full comparative 
pediatric economic evaluations. Cost-effectiveness analyses (CEAs) represent 66% 
and CUAs 22% of studies. The proportion of CUAs has grown over time, from 0% in 
1980 to 54% in 2012, with an average annual growth rate of 30% since 2002. Before 
2004, CUAs constituted fewer than 15% of pediatric health economic evaluations. 
In 2009 CUAs overtook CEAs as the most common analytic technique. In contrast, 
cost-benefit analyses accounted for 27% of studies between 1980 and 1990 and 
this decreased to 2% in 2012. A total of 1,420 health states were described in 559 
CUAs published between 1980 and 2012, but only 60% included utility weights. The 
majority of these weights were derived from other published sources, including 
adult studies. cOnclusiOns: The volume of pediatric CUAs has grown significantly 
since 1980 and CUAs now surpass CEAs as the most common technique for child 
health economic evaluation. However, few CUAs elicit utilities prospectively and 
rely instead on other published studies of unknown quality. Improved methods 
for eliciting utilities for child health states and the creation of a repository of valid 
utility weights will contribute to higher quality pediatric CUAs for decision-making.
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